Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 244

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 244
---
 as they own preferred shares. The investor also has the right to
participate in up to 50% of future offerings for one year following the closing. We agreed not to enter into an equity line of credit
or similar agreement without the consent of the majority of the preferred shareholders. This transaction also closed on October 10, 2024.

On
October 9, 2024, the Company and certain existing warrant holders entered into warrant amendment agreements, or collectively, the October
Warrant Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843 common shares issued
to such holders, or the Existing Warrants. The October Warrant Amendment makes certain adjustment to the definition of a “ Fundamental
Transaction” in Section 3(e) of the Existing Warrants. In exchange for the Amendment, the Company agreed to adjust the exercise
price in the Common Warrants to CHF 0.80 and issued to the holders Pre-Funded Warrants to purchase up to 136,648 common shares, or the
October Pre-Funded Warrants. Each October Pre-Funded Warrant is exercisable for one Common Share at an exercise price of CHF 0.80 per
share. The October Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the October Pre-Funded
Warrants are exercised in full.

On
October 10, 2024, we successfully implemented a restructuring measure by converting the claims of related party debt holders in the amount
of $2,788,650 into 493,986 common shares. This conversion was facilitated through an ordinary capital increase, providing the necessary
shares for the debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations.

On
December 4, 2024, we entered into a securities purchase agreement with an accredited investor, providing for the issuance in a
private placement offering of 322,580 registered common shares, at a purchase price of $3.10 per common share, for aggregate gross
proceeds of up to $1 million. The offering was structured in two tranches, with the first tranche of $500,000 closing in January
2025 following shareholder approval. The proceeds from the offering were intended to support our general corporate purposes and our
proposed merger with Kadimastem. The second tranche of $500,000 may occur, at the election of